JAC Advance Access originally published online on July 29, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 450-456
© 2003 The British Society for Antimicrobial Chemotherapy
Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects
1 Pulmonary Associates and 2 School of Medicine, University of Arizona, Phoenix, AZ; Colleges of 3 Pharmacy and 4 Medicine, University of Illinois, 833 South Wood Street, Chicago, IL 60612, USA
Received 6 January 2003; returned 15 April 2003; revised 19 May 2003; accepted 2 June 2003
Objectives: The steady-state concentrations of clarithromycin in plasma were compared with concomitant concentrations in epithelial lining fluid (ELF) and alveolar macrophages (AM) obtained from intrapulmonary samples during bronchoscopy and bronchoalveolar lavage (BAL). Concentrations of the major metabolite, 14-hydroxyclarithromycin, were also determined in plasma and AM.
Materials and methods: Forty-two healthy, non-smoking adult subjects (age: 18–54 years; 19 females, 23 males) received oral clarithromycin extended-release formulation (1000 mg once daily for five consecutive days). Bronchoscopy and BAL were carried out once in each subject at either 3, 6, 9, 12, 24 or 48 h after the last administered dose of clarithromycin. In addition, three subjects who did not take clarithromycin served as controls and underwent bronchoscopy at 0 h. Drug concentrations in plasma, ELF, and AM were determined by high-performance liquid chromatography.
Results: Clarithromycin was extensively concentrated in ELF [range of mean (±S.D.) concentrations: 6.38 ± 3.92 to 11.50 ± 6.65 mg/L] and AM (127.0 ± 61.5 to 573.8 ± 309.3 mg/L) than simultaneous plasma concentration (0.75 ± 0.31 to 2.22 ± 0.72 mg/L). The ranges of mean (±S.D.) concentrations of 14-hydroxyclarithromycin in plasma and AM were 0.52 ± 0.29 to 0.80 ± 0.31 mg/L and 22.1 ± 13.5 to 49.5 ± 16.2 mg/L, respectively.
Conclusions: Once-daily dosing of extended-release formulation clarithromycin 1000 mg produced significantly (P < 0.05) higher steady-state concentrations of clarithromycin in ELF (2–14 times) and AM (50–700 times) compared to simultaneous plasma concentrations throughout the 24 h period after drug administration. The 14-hydroxy metabolite of clarithromycin achieved significantly (P < 0.05) higher steady-state concentrations in AM (18–180 times) compared with concurrent plasma concentrations.
Keywords: pharmacokinetics, bronchoscopy, epithelial lining fluid, alveolar macrophages
* Correspondence address. m/c 886, Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, Room 164, 833 South Wood Street, Chicago, IL 60612, USA. Tel: +1-312-996-3341; Fax: +1-312-413-1797; E-mail: kar{at}uic.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]
|
|